Introduction: Intermittent detection of hepatitis B viral DNA aft er suppression to undetectable viral level raises concerns about inadequate viral suppression, viral breakthrough, resistance, or noncompliance. Th is retrospective review was conducted in order to characterize the frequency and clinical significance of this laboratory fi nding, which will be referred to as intermittency pattern (IP). Methods: Patients with hepatitis B seen in an outpatient hepatology practice from April 2015 to 2016 who had been treated or were undergoing treatment with oral nucleos(t)ides were included for review. Patients who did not attain viral suppression < 20 IU/ml by PCR amplifi cation for quantitative HBV DNA were excluded. Results: A total of 61 patients with HBV were identifi ed. 10 did not require treatment, another 10 did not achieve viral suppression to < 20 IU/ml. Th e fi nal study included 41 patients, ranging in age from 33 to 96 years (median 53), 51% female, and HBeAg positive in 27% at time of initiation of therapy. Th irtyeight (93%) were treated with a regimen that included either tenofovir (N=29) or entecavir (N=8) or both (N=1), the remainder were treated with lamivudine or adefovir (N=3). 83% (N=34) reached undetectable viral load, while the remainder had detectable HBV DNA but < 20 IU/ ml at nadir. Of these 34 patients, 50% (N=17) demonstrated IP, with median of 2 occasions of detectable DNA aft er reaching undetectable level. In all of these cases, viral load was < 20 IU/ml but detectable on PCR. None had concurrent elevation in ALT or symptoms at times of viral detectability. In those with IP, median age was 55 years, 58% were female, HBeAg was present in 23%, 6% had cirrhosis, and median time to reach viral suppression < 20 IU/ml was 2 years. In those without IP (N=17) median age was 52 years, 41% were female, HBeAg was present in 29%, and 17% had cirrhosis. Conclusion: 50% of patients with long term viral suppression demonstrated IP by PCR. Th ere was a slight female predominance and fewer patients with cirrhosis in patients with IP compared to those without. Possible explanations for the IP phenomenon include low level of viral replication fl uctuating around the level of detectability in patients whose virus is adequately suppressed by treatment, incomplete medication compliance, and false positivity of the assay. Given that IP was not associated with concurrent elevation of ALT, symptoms, or quantifi able viral level, IP appears to have little clinical signifi cance.
Rowena Almeida, MD 1 , Ambreen Arif, BSc 2 , Angela Cheung, MD, FRCPC 2 . 1. University of Toronto, Toronto, ON, Canada; 2. University of Toronto, University Health Network, Toronto, ON, Canada. Introduction: Classically, the presence of cholelithiasis favors a diagnosis of secondary rather than primary sclerosing cholangitis (PSC), but up to 8% of patients with PSC may have cholelithiasis.
Our aim was to determine whether PSC patients with and without cholelithiasis are distinct entities with diff erent outcomes. Methods: A retrospective cohort study was conducted with adults with large-duct PSC. Cholelithiasis & disease distribution were determined with baseline & follow-up imaging. Cox regression was used to determine predictors of poor composite outcome (decompensation, liver-related death or transplant). Results: 112/198 charts were included (67 no cholelithiasis [NCL]; 45 cholelithiasis [CL]). Less women had CL (p=.005); there were no other diff erences in baseline parameters (ie. disease distribution (p=.54), infl ammatory bowel disease (IBD) (p=.89), type of IBD (p=.53). Over 50% of patients with cholelithiasis had right sided disease. By the end, the CL group was more likely to be cirrhotic (62% vs 42%, p=.03), worse symptoms (jaundice, fatigue, pruritus, cholangitis), and two-fold higher alkaline phosphatase (ALP) and transaminases (AST and ALT). 18% of the CL group required 2 or more ERCPs, compared to only 5% of the NCL group (p=.02). Both had similar rates of hepatobiliary cancer (p =.73). Cholelithiasis independently predicted worse outcome (HR 2.6, 95%CI 1.3-5.4, p= 0.008), aft er adjusting for age at diagnosis, baseline cirrhosis & ALP. Adjusting models for sex, ethnicity and cumulative use of ursodeoxycholic acid (UDCA) resulted in similar hazard ratios for cholelithiasis. Conclusion: PSC with cholethiasis is a distinct phenotype of PSC, with worse symptoms and composite outcome. Th e presence of cholethiasis may partly explain the variability in the natural history of PSC across diff erent studies. Modifi cation of bile lithogenicity with therapies such as UDCA may alter symptom profi le and prognosis in certain patients with PSC.
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Real-World Sovaldi-Based Management of hCv-Infected Patients in Pakistan (ReSCIP Study)
Bilal Nasir, MBBS 1 , Ghias Un Nabi Tayyab, MBBS,MRCP 1 , Shafqat Rasool, MBBS 2 . 1. Doctor's Hospital and Medical Center & Post Graduate Medical Institute, Lahore, Punjab, Pakistan; 2. Post Graduate Medical Institute, Lahore, Punjab, Pakistan. Introduction: With the availability of DAA's, there has been a paradigm shift in the management of HCV infected pts. In resource poor countries with high disease burden of HCV, availability of sofosbuvir at subsidized price made it possible to treat HCV infected pts. We present initial real world data of sofosbuvir based anti HCV treatment. Methods: 433 eligible pts. enrolled in the outpatient clinics of DHMC & LGH, Lahore were off ered the sofosbuvir based triple (12 weeks) or dual (24 weeks) treatment according to the national guidelines and preferences of the patient aft er an informed consent from Oct 2014 to Dec 2015. Pts were declared cirrhotic on APRI score and SWE. Pts with ESLD, HCC, active bacterial sepsis, pregnancy, moderate renal failure (Creatinine clearance < 35ml/min) and HB < 11 gm/dl were excluded. Th e DCLD pts were treated for the their complications like ascites or encephalopathy before initiating the HCV treatment. Pts were followed up on monthly interval during the course of treatment and 6 weekly for 12 weeks aft er the completion of therapy for the side eff ects, blood counts, creat and liver biochemistry. USG evaluation for focal defect and ascites was done at base line and aft er three months each or when needed in patients suff ering from liver cirrhosis.HCV RNA was analyzed with Cepheid Xpert and Taqman 20 Roche cobas 2 techniques (detection limit of 5 iu/ml). Results: Mean age of the Pts was 48.51 (range 14-76), mean weight 72.05 kg (37-136) and a male to female ratio of 1:1. Genotype 3 was the commonest (77.13%) (Fig 1, Pie chart) followed by gen 1 (6.2%), gen 4 (1.8 %), gen 2, gen U, gen 6 and mixed for 1 &3 (0.06 % each). 175/433 (40.14%) had APRI & SWE score falling in to cirrhosis. 428/433 (99.43 %) Pts were able to complete the therapy. Th e detailed results for the genotype 3 & 1 in fi g2 & 3 respectively. 20 pts (4.61 %) decompensated on treatment, new HCC was seen in 24 cirrhotic Pts (13.71%) and 3 Pts died as a result of decompensation. Anemia requiring dose adjustment of ribavirin or additional EPO (30.63%) and fever (19.36%) are the commonest side eff ects in Sof and RBV group while fever (63.55%) and fl u like symptoms (31.35%) are the commonest side eff ects in IFN group. Conclusion: 24 weeks Sofosbuvir & Ribavirin is eff ective in gen 3 treatment naïve early HCV & compensated cirrhotics. Th e effi cacy reduces with the history of previous exposure to IFN and severity of disease. Cirrhotic Pts are at enhanced risk of HCC.
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